Inverse psoriasis: possibilities of modern therapy
https://doi.org/10.33667/2078-5631-2025-23-68-72
Abstract
Introduction. Management of patients with inverse psoriasis presents a significant challenge due to diagnostic complexity and pronounced psycho‑emotional distress. Current clinical guidelines recommend zinc pyrithione as one therapeutic option.
Objective. To demonstrate the clinical efficacy of activated zinc pyrithione–based medications (Skin‑Cap) in patients with inverse psoriasis.
Materials and methods. This article describes seven clinical cases involving various formulations of Skin‑Cap, used either as monotherapy or in combination with other drugs.
Results. The reported clinical observations show high efficacy and safety of Skin‑Cap in multiple topical forms (aerosol, cream, shampoo, shower gel) for treating inverse psoriasis, in both short‑term and long‑term use.
Conclusions. The use of Skin‑Cap in the topical treatment of inverse psoriasis is pathogenetically justified, minimizes the risk of adverse effects, and significantly improves patients’ quality of life.
About the Author
O. I. Letyaeva
South Ural State Medical University
Russian Federation
Russian Federation
Letyaeva Olga I., DM Sci (habil.), associate professor, professor at Dept of Dermatovenereology
Chelyabinsk
References
1. Psoriasis: clinical guidelines. Ministry of Health of the Russian Federation. All Russian public organization «Russian Society of Dermatovenerologists and Cosmetologists»; 2023. (In Russ.). https://cr.minzdrav.gov.ru/preview-cr/234_2
2. Khlebnikova AN. Psoriasis of the folds: diagnostic value of dermatoscopic examination, experience of using a combined topical drug (series of clinical observations). Almanac of Clinical Medicine. 2022; 50 (7): 447–454. (In Russ.). DOI: 10.18786/2072-0505-2022-50-032.
3. Da Silva N, Augustin M, Hilbring C, Braren von Stülpnagel CC, Sommer R. Psychological (co)morbidity in patients with psoriasis: the impact of pruritus and anogenital involvement on symptoms of depression and anxiety and on body dysmorphic concerns – a cross sectional study. BMJ Open. 2022 Sep 23; 12 (9): e055477. DOI: 10.1136/bmjopen-2021–055477. PMID: 36153012; PMCID: PMC9511542.
4. Dopytalska K., Sobolewski P., Błaszczak A., Szymańska E., Walecka I. Psoriasis in special localizations. Reumatologia. 2018; 56 (6): 392–398.
5. Wu M, Fischer G. Adult genital psoriasis: An updated review for clinicians. Australas J Dermatol. 2024 May; 65 (3): e1 e12. DOI: 10.1111/ajd.14227. Epub 2024 Feb 28. PMID: 38419192.
6. Khosravi H, Siegel MP, Van Voorhees AS, Merola JF. Treatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation. J Drugs Dermatol. 2017; 16 (8): 760–766.
7. Meeuwis KAP, Potts Bleakman A., van de Kerkhof PCM, Dutronc Y., Henneges C., Kornberg L.J., Menter A. Prevalence of genital psoriasis in patients with psoriasis. Journal of Dermatological Treatment. 2018; 29 (8): 754–760.
8. Shah SFH., Merchant S.A., Shah, S.A. Female sexual dysfunction in psoriasis: a systematic review and meta analysis using the Female Sexual Function Index.International Journal of Impotence Research. 2024; 36 (3): 232–241.
9. Janeczek M, Kozel Z, Bhasin R, Tao J, Eilers D, Swan J. High Prevalence of Erythrasma in Patients with Inverse Psoriasis: A Cross sectional Study. J Clin Aesthet Dermatol. 2020; 13 (3): 12–14.
10. Kudrdina M.I. Kolenko N.G. Psoriaz anogenitalnoj zony. Opyt lecheniya netakimabom. Medicinskij alfavit. 2025 (8) 888. (In Russ.). https://doi.org/10./208-512025-8-8-88
11. Kruglova L.S., Bakulev A.L., Kokhan M.M., Lvov A.N., Murashkin N. N., Olisova O. Yu., Rakhmatulina M. R., Samtsov A. V., Sokolovsky E.V. Expert Consensus on practical issues of using topical activated zinc pyrithione in dermatology. Medical alphabet. 2025;(8):126–130. (In Russ.) https://doi.org/10.33667/2078-5631-2025-8-126-130
12. Ferrara F., Verduci C., Laconi E., Mangione A., Dondi C., Del Vecchio M., Carlevatti V., Zovi A., Capuozzo M., Langella R. Current therapeutic overview and future perspectives regarding the treatment of psoriasis. International Immunopharmacology. 2024; 143 (1): 113388.
13. Menter A., Gelfand J.M., Connor C., Armstrong A.W., Cordoro K.M., Davis DMR, Elewski B.E., Gordon K.B., Gottlieb A.B., Kaplan D.H. et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal of the American Academy of Dermatology. 2020; 82: 1445–1486.
14. Hong J.J., Mosca M.L., Hadeler E.K., Brownstone N.D., Bhutani T., Liao W.J. Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. Dermatology and Therapy (Heidelb). 2021; 11 (3): 833–844.
15. Gottlieb A.B., Kirby B., Ryan C. et al. The Development of a patient-reported outcome measure for assessment of genital psoriasis symptoms: The Genital Psoriasis Symptoms Scale (GPSS). Dermatology and Therapy (Heidelb). 2018; 8: 45–56.
16. Kruglova LS, Gryazeva NV, Uspenskaya PA Topical therapy of psoriasis: algorithms for the use of activated zinc pyrithione. Medical alphabet. 2024; (25):59–64. (In Russ.).
17. Alekseyenko AV, Perez-Perez GI, De Souza A, Strober B, Gao Z, Bihan M, Li K, Methé BA, Blaser MJ. Community differentiation of the cutaneous microbiota in psoriasis. Microbiome.2013;1(1):31. DOI: 10.1186/2049 2618 1 31
18. Letyaeva O.I. Rol’ infekcionnyh agentov v patogeneze dermatozov u detej i podrostkov. Detskie infekcii. 2020;19(3):58–64. (In Russ.).
19. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, Ståhle Bäckdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004; 19 (3): 225–230. DOI: 10.1023/b:ejep.0000020447.59150.f9
20. Kelly A., Ryan C. Genital Psoriasis: Impact on Quality of Life and Treatment Options. American Journal of Clinical Dermatology. 2019; 20 (5): 639–646.
21. Registration number of the accreditation certificate No. ROSS RU. 001.21 AYu22 (State Standard of Russia). (In Russ.).
22. Zhukov A. S., Khairutdinov V. R., Samtsov A. V. Comparative study of the anti inflammatory activity of zinc pyrithione in a laboratory model of psoriasis. 2020; (2): 64–70. (In Russ.).
23. Park M, Cho YJ, Lee YWUnderstanding the Mechanism of Action of the Anti Dandruff Agent Zinc Pyrithione against Malassezia restricta. Sci Rep. 2018 Aug 14; 8 (1): 12086
Review
For citations:
Letyaeva O.I. Inverse psoriasis: possibilities of modern therapy. Medical alphabet. 2025;1(23):68-72. (In Russ.) https://doi.org/10.33667/2078-5631-2025-23-68-72
Views:
13
Email this article 